TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31689242

Group type: EXPERIMENTAL
Intervention: Third-party EBV-specific cytotoxic T-lymphocytes (EBV-CTLs)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Third-party EBV-specific cytotoxic T-lymphocytes (EBV-CTLs) from a different donor (switch therapy)
Number of subjects: 46
Study: 31689608

Group type: EXPERIMENTAL
Intervention: ADHEAR system
Number of subjects: 10

Group type: COMPARATOR
Intervention: BCHA on a softband
Number of subjects: 10
Study: 31689797

Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Fully covered self-expandable metallic stents
Number of subjects: 2
Study: 31689809

Group type: EXPERIMENTAL
Intervention: MESA questionnaire (translated and culturally adapted version)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical extended assessment, 3-day voiding diary, International Consultation on Incontinence Questionnaire Short Form
Number of subjects: 0
Study: 31689874

Group type: EXPERIMENTAL
Intervention: VisionSense VS3 NIRFI device for SLN identification
Number of subjects: 93

Group type: COMPARATOR
Intervention: Lymphoscintigraphy (gold standard)
Number of subjects: 93
Study: 31690104

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 8530

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 8530

Group type: EXPERIMENTAL
Intervention: TAVR and SAVR
Number of subjects: 8530
Study: 31690284

Group type: EXPERIMENTAL
Intervention: Phenylephrine 2.5% plus tropicamide 0.5%
Number of subjects: 60
Study: 31690286

Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT) - 100% oxygen at 2 atm absolute (ATA) for 90 minutes, 20 sessions for 5 days per week, followed by a second cycle of 20 sessions after 1 week of suspension.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT)
Number of subjects: 12
Study: 31690524

Group type: EXPERIMENTAL
Intervention: Treovance stent graft (for FNA patients)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Treovance stent graft (for HNA patients)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Treovance stent graft (for both groups)
Number of subjects: 200
Study: 31690590

Group type: EXPERIMENTAL
Intervention: Severe early childhood caries (ECC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Caries-free children (control)
Number of subjects: 44
Study: 31690644

Group type: EXPERIMENTAL
Intervention: Ultrasonographic examination in group Y (aged under 40 years)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ultrasonographic examination in group O (aged over 60 years)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Position (lateral and sitting)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Spinal level (L3/4, L4/5, L5/S1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laterality (right and left paramedian sagittal oblique view)
Number of subjects: 40
Study: 31690685

Group type: COMPARATOR
Intervention: Fewest comorbidities class (reference group)
Number of subjects: 0
Study: 31690697

Group type: EXPERIMENTAL
Intervention: Anti-FGFR3 antibodies positive patients (65 out of 426)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Anti-FGFR3 antibodies negative patients (361 out of 426)
Number of subjects: 426
Study: 31690932

Group type: COMPARATOR
Intervention: Early stage NAFLD
Number of subjects: 49

Group type: COMPARATOR
Intervention: NASH
Number of subjects: 49

Group type: COMPARATOR
Intervention: NAFLD patients with liver fibrosis
Number of subjects: 49
Study: 31691133

Group type: COMPARATOR
Intervention: Low-dose formulation
Number of subjects: 25

Group type: COMPARATOR
Intervention: High-dose formulation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 31691148

Group type: EXPERIMENTAL
Intervention: Steep head-down position with pneumoperitoneum during laparoscopic radical prostatectomy (LRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31691892

Group type: EXPERIMENTAL
Intervention: ddPCR assay for T790M mutation in plasma
Number of subjects: 62
Study: 31691897

Group type: EXPERIMENTAL
Intervention: IKORUS UP probe (urethral photoplethysmography-derived perfusion device)
Number of subjects: 30
Study: 31692269

Group type: EXPERIMENTAL
Intervention: GAHT with TDF/FTC
Number of subjects: 16

Group type: COMPARATOR
Intervention: TDF/FTC
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: On demand (2 + 1 + 1) PrEP regimen with GAHT
Number of subjects: 16
Study: 31693319

Group type: EXPERIMENTAL
Intervention: Cryoballoon
Number of subjects: 89

Group type: COMPARATOR
Intervention: Radiofrequency current (RFC)
Number of subjects: 89
Study: 31693389

Group type: EXPERIMENTAL
Intervention: Visual biofeedback via electropalatography (EPG)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sound Production Treatment (SPT)
Number of subjects: 2
Study: 31693535

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 3011

Group type: EXPERIMENTAL
Intervention: Nebivolol as monotherapy in de novo patients
Number of subjects: 3011

Group type: EXPERIMENTAL
Intervention: Nebivolol as add-on therapy to existing antihypertensives
Number of subjects: 3011
Study: 31693621

Group type: EXPERIMENTAL
Intervention: [18F]FAZA PET/CT imaging
Number of subjects: 1
Study: 31694553

Group type: EXPERIMENTAL
Intervention: RARC
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (open abdominal surgery in horizontal positioning)
Number of subjects: 47
Study: 31694664

Group type: EXPERIMENTAL
Intervention: Involuntarily admitted patients
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Voluntarily admitted patients
Number of subjects: 202

Group type: COMPARATOR
Intervention: Both groups (involuntarily and voluntarily admitted)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Stage of readiness to change at admission
Number of subjects: 202

Group type: COMPARATOR
Intervention: SUD severity at baseline
Number of subjects: 202
Study: 31694844

Group type: EXPERIMENTAL
Intervention: Few-Foods Diet (FFD)
Number of subjects: 100
Study: 31694860

Group type: EXPERIMENTAL
Intervention: Dietary patterns of insulin pump users
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary patterns of multiple daily injection users
Number of subjects: 0
Study: 31694954

Group type: EXPERIMENTAL
Intervention: Immunotherapies and gene therapies
Number of subjects: 39600000

Group type: EXPERIMENTAL
Intervention: Vaccine research, viral transcript editing, T-cell effector response targeting including checkpoint inhibitors, and gene editing
Number of subjects: 39600000

Group type: EXPERIMENTAL
Intervention: Targeting HIV-1 tissue reservoirs
Number of subjects: 39600000
Study: 31695074

Group type: COMPARATOR
Intervention: Controlled asthma
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Partially controlled asthma
Number of subjects: 203
Study: 31695346

Group type: EXPERIMENTAL
Intervention: Low density lipoprotein (LDL)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 105
Study: 31695347

Group type: EXPERIMENTAL
Intervention: Delirium group (patients with delirium)
Number of subjects: 760
Study: 31695439

Group type: EXPERIMENTAL
Intervention: Single-use autoinjector (AI) for benralizumab 30 mg
Number of subjects: 121
Study: 31695667

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (sham stimulation)
Number of subjects: 0
Study: 31697246

Group type: EXPERIMENTAL
Intervention: Home-Based cardiac rehabilitation (2 supervised sessions and 58 home sessions, guided by telephone)
Number of subjects: 72

Group type: COMPARATOR
Intervention: CenterRehab (traditional supervised cardiac rehabilitation, 24 supervised sessions and 36 home sessions)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Home-Based cardiac rehabilitation
Number of subjects: 72

Group type: COMPARATOR
Intervention: CenterRehab
Number of subjects: 72
Study: 31697308

Group type: EXPERIMENTAL
Intervention: BMS-986156 monotherapy
Number of subjects: 292

Group type: COMPARATOR
Intervention: BMS-986156 plus nivolumab
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: BMS-986156 with or without nivolumab
Number of subjects: 292
Study: 31697383

Group type: EXPERIMENTAL
Intervention: Machine learning risk score
Number of subjects: 75558

Group type: EXPERIMENTAL
Intervention: Model-based risk score
Number of subjects: 75558

Group type: EXPERIMENTAL
Intervention: Risk-group strategy
Number of subjects: 75558
Study: 31697647

Group type: EXPERIMENTAL
Intervention: CMV-stimulated IFN-γ response
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: CMV-specific IFN-γ response
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: CMV ELISpot-positive infants
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: CMV ELISpot-negative infants
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: CMV- signature
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: 16-gene signature
Number of subjects: 178
Study: 31698104

Group type: EXPERIMENTAL
Intervention: Concentrations of IL-1β in endometrial secretion
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Concentrations of TNF-α in endometrial secretion
Number of subjects: 120
Study: 31698328

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 1037
Study: 31698334

Group type: EXPERIMENTAL
Intervention: Incentive
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Incentive with feedback
Number of subjects: 24

Group type: COMPARATOR
Intervention: Self-monitoring
Number of subjects: 24
Study: 31698337

Group type: EXPERIMENTAL
Intervention: Cadence threshold of ≥100 steps/min
Number of subjects: 75
Study: 31698454

Group type: EXPERIMENTAL
Intervention: Etranacogene dezaparvovec (2 × 10^13 genome copies/kg)
Number of subjects: 3
Study: 31698933

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 3828

Group type: EXPERIMENTAL
Intervention: Catheter Ablation (CA)
Number of subjects: 3828

Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 3828

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3828
Study: 31698986

Group type: EXPERIMENTAL
Intervention: DWI-ASPECTS and ischemic core volume assessment
Number of subjects: 0
Study: 31699157

Group type: COMPARATOR
Intervention: Automated tablet audiometer
Number of subjects: 124

Group type: COMPARATOR
Intervention: Tablet audiometer for monosyllabic word recognition testing
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Automated tablet audiometric evaluation
Number of subjects: 124
Study: 31699278

Group type: EXPERIMENTAL
Intervention: Women with de novo heart failure at hospital presentation
Number of subjects: 10443

Group type: COMPARATOR
Intervention: Men with de novo heart failure at hospital presentation
Number of subjects: 10443

Group type: EXPERIMENTAL
Intervention: Women with de novo heart failure
Number of subjects: 10443

Group type: COMPARATOR
Intervention: Men with de novo heart failure
Number of subjects: 10443

Group type: EXPERIMENTAL
Intervention: Women with de novo heart failure undergoing reperfusion therapy
Number of subjects: 10443

Group type: COMPARATOR
Intervention: Men with de novo heart failure undergoing reperfusion therapy
Number of subjects: 10443
Study: 31699696

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) measured using the EuroQol five-dimension questionnaire at hospitalisation, 1, 6 and 12 months post-AMI.
Number of subjects: 9566

Group type: EXPERIMENTAL
Intervention: Reduced HRQoL associated with various factors including gender and comorbidities.
Number of subjects: 9566

Group type: EXPERIMENTAL
Intervention: Latent class growth analysis (LCGA) identified subgroups of HRQoL.
Number of subjects: 9566
Study: 31699743

Group type: EXPERIMENTAL
Intervention: Conditional cash transfers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Status quo (no cash transfers)
Number of subjects: 0
Study: 31699745

Group type: EXPERIMENTAL
Intervention: Obese pregnant women (BMI ≥30 kg/m²)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Non-obese pregnant women
Number of subjects: 188
Study: 31699827

Group type: EXPERIMENTAL
Intervention: AZD4573 (highly selective CDK9 inhibitor)
Number of subjects: 0
Study: 31700871

Group type: EXPERIMENTAL
Intervention: JS001 at 10 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: JS001 at 3 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: JS001 (all doses)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: JS001 (PD-L1 positive subjects)
Number of subjects: 20
Study: 31700924

Group type: EXPERIMENTAL
Intervention: Taodan granules (TDKL), administered twice per day, 7 days per week, for 8 weeks.
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo, administered twice per day, 7 days per week, for 8 weeks.
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Taodan granules (TDKL) and Placebo, both administered twice per day, 7 days per week, for 8 weeks.
Number of subjects: 216
Study: 31701043

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) dressing (PICO™, Smith & Nephew, UK)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Standard wound dressing
Number of subjects: 491
Study: 31701169

Group type: EXPERIMENTAL
Intervention: Radiotherapy dose reduced to cumulative 60 Gy with simultaneous chemotherapy regimen of cisplatin 30 mg/m²
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard multimodal treatments
Number of subjects: 0
Study: 31701294

Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR) Fidelity scale
Number of subjects: 0
Study: 31701679

Group type: EXPERIMENTAL
Intervention: Connect MM Registry
Number of subjects: 3011

Group type: COMPARATOR
Intervention: SEER and NCDB databases
Number of subjects: 3011
Study: 31702640

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture on the highest sensitized acupoints after 20 sessions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 30
Study: 31703570

Group type: EXPERIMENTAL
Intervention: Reconsolidation Therapy (RT) - involves recalling traumatic events with propranolol, once a week for 10-25 minutes over 6 weeks
Number of subjects: 400

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 400
Study: 31703604

Group type: EXPERIMENTAL
Intervention: Domatinostat combined with pembrolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Domatinostat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Domatinostat for 14 days in patients
Number of subjects: 0
Study: 31703606

Group type: EXPERIMENTAL
Intervention: Active tube clearance (Phase 2)
Number of subjects: 697
Study: 31703628

Group type: EXPERIMENTAL
Intervention: Histological examination of thrombus formation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Immunofluorescence method for factor VIII and fibrinogen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Histological examination of thrombus
Number of subjects: 30
Study: 31703637

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg followed by palliative radiotherapy with 5 × 4 Gray (Gy) = 20 Gy photon radiation (Group A)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Nivolumab (Group B)
Number of subjects: 130
Study: 31703728

Group type: EXPERIMENTAL
Intervention: Combination of eribulin (1.4 mg/m² daily) and everolimus (5 mg daily) at dose level A1
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of eribulin and everolimus at dose level A2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of eribulin and everolimus at dose level B1
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of eribulin and everolimus
Number of subjects: 27
Study: 31703971

Group type: EXPERIMENTAL
Intervention: Surgical treatment of RCC
Number of subjects: 1943

Group type: EXPERIMENTAL
Intervention: Age, pathological T3/4 stage, pathological N1/2 stage, Fuhrman grades 3 and 4
Number of subjects: 1943
Study: 31704134

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously once every 4 weeks, with loading doses on days 8 and 15 for cohorts 1 and 2.
Number of subjects: 532
Study: 31704214

Group type: EXPERIMENTAL
Intervention: Super-boosted lopinavir/ritonavir (LPV/r) 400/400 mg
Number of subjects: 0
Study: 31704699

Group type: EXPERIMENTAL
Intervention: HMC group
Number of subjects: 94

Group type: COMPARATOR
Intervention: ARC group
Number of subjects: 94
Study: 31705425

Group type: EXPERIMENTAL
Intervention: Myocardial substrate metabolism in BTHS
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (unaffected individuals)
Number of subjects: 14
Study: 31705521

Group type: EXPERIMENTAL
Intervention: DOAC Dipstick pads
Number of subjects: 914

Group type: COMPARATOR
Intervention: Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
Number of subjects: 914
Study: 31705547

Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide (IDegLira) starting dose of 16 units
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide (IDegLira)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31705738

Group type: EXPERIMENTAL
Intervention: Electrochemical Skin Conductance (ESC) measured in microsiemens (µS) with Sudoscan
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing (QST) of cold and warm detection and pain thresholds
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Psychological, quality of life, sleep, and social characteristics assessments
Number of subjects: 50
Study: 31705855

Group type: EXPERIMENTAL
Intervention: STOPBANG score
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Multivariable Apnea Prediction Index (MAPI)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Berlin high-risk score
Number of subjects: 248
Study: 31706057

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Vertical sleeve gastrectomy (VSG)
Number of subjects: 226
Study: 31706060

Group type: EXPERIMENTAL
Intervention: Single-use duodenoscope
Number of subjects: 73

Group type: COMPARATOR
Intervention: Single-use duodenoscope followed by crossover to reusable duodenoscope
Number of subjects: 73
Study: 31706318

Group type: EXPERIMENTAL
Intervention: Nurses' perceptions of their role in addressing childhood overweight/obesity
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Nurses' perceptions of organizational barriers
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Recommendations for improving care
Number of subjects: 442
Study: 31706360

Group type: EXPERIMENTAL
Intervention: Swallowing and oral care (SOC) intervention
Number of subjects: 171

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 171
Study: 31706582

Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration
Number of subjects: 0
Study: 31707159

Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 105
Study: 31707795

Group type: EXPERIMENTAL
Intervention: Canagliflozin, dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, treatment not specified
Number of subjects: 0
Study: 31707833

Group type: EXPERIMENTAL
Intervention: Stent thrombosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31707942

Group type: EXPERIMENTAL
Intervention: Resuscitative endovascular balloon occlusion of the aorta (REBOA) during cardiopulmonary resuscitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advanced cardiac life support
Number of subjects: 0
Study: 31707975

Group type: EXPERIMENTAL
Intervention: Ruxolitinib, 20 mg orally twice daily for a 28-day cycle, continued for up to 16 cycles or until progressive disease or intolerability.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ruxolitinib in HL patients with JAK2 amplification.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ruxolitinib in PMBCL patients.
Number of subjects: 19
Study: 31707980

Group type: EXPERIMENTAL
Intervention: Pressure pain threshold in the neck (measured at four standardized points)
Number of subjects: 372
Study: 31708167

Group type: EXPERIMENTAL
Intervention: Veliparib (250 mg BID) with chemotherapy (Regimen 1, continuous dosing)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Veliparib (400 mg BID) with chemotherapy (Regimen 1, intermittent dosing)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Veliparib (150 mg BID) with weekly paclitaxel (Regimen 2, continuous dosing)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Veliparib (250 mg BID) with weekly paclitaxel (Regimen 2, intermittent dosing)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Veliparib (150 mg BID) with intraperitoneal chemotherapy (Regimen 3, continuous dosing)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Veliparib (400 mg BID) with intraperitoneal chemotherapy (Regimen 3, intermittent dosing)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Veliparib (150 mg po BID) with chemotherapy (Regimens 1c, 2c, 2i, and 3c)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Veliparib (250 mg po BID) with chemotherapy (Regimen 1i)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Veliparib (300 mg po BID) with chemotherapy (Regimen 3i)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Comparison of continuous vs intermittent dosing of veliparib
Number of subjects: 424
Study: 31708188

Group type: EXPERIMENTAL
Intervention: TriClip tricuspid valve repair system
Number of subjects: 85
Study: 31708296

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (200 mg for three courses)
Number of subjects: 114
Study: 31708735

Group type: EXPERIMENTAL
Intervention: Robot-assisted stair climbing training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sensory integration balance training
Number of subjects: 32
Study: 31708810

Group type: EXPERIMENTAL
Intervention: ACCESS Integrated Care Model including Therapeutic Assertive Community Treatment
Number of subjects: 0
Study: 31708812

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31708824

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brain-Derived Neurotrophic Factor (BDNF) levels
Number of subjects: 0
Study: 31708890

Group type: EXPERIMENTAL
Intervention: Narrow Band Ultraviolet B (NB-UVB) light exposure
Number of subjects: 0
Study: 31709259

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (800 IU daily for 6 months)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 31709648

Group type: EXPERIMENTAL
Intervention: 5 mg glipizide
Number of subjects: 786